Onconova Announces Ten Presentations at the 2014 ASH Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Onconova Announces Ten Presentations at the 2014 ASH Annual Meeting

--Phase 3 ONTIME Trial Data Selected for Oral Presentation--

--Data from Phase 1/2 Trial of Oral Rigosertib and Azacitidine Combination Highlighted--

NEWTOWN, Pa., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX ), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that ten abstracts were selected for presentation at the 56 th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014. The key presentations include the first detailed description of Phase 3 results from the ONTIME study of IV rigosertib in higher risk MDS, safety and efficacy data from the Phase 1 combination trial of oral rigosertib and azacitidine in MDS and AML, as well as studies with oral rigosertib in lower risk MDS.

Phase 3 ONTIME Trial Presentations:

Abstract #163

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-risk Myelodysplastic Syndrome (HR-MDS) After Failure of Hypomethylating Agents (HMAs)  

Date:  Sunday, December 7, 2014
Presentation Time: 4:30 PM
Session:  637. Myelodysplastic Syndromes – Clinical Studies: Clinical Studies and Disease Characterization
Location:  San Francisco Marriott Marquis, Yerba Buena Ballroom Salon 7
Presenter: Guillermo Garcia-Manero, MD, MD Anderson Cancer Center, Houston, TX


Abstract #3258

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy

Date: Sunday, December 7, 2014
Time:  6:00 PM - 8:00 PM
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Location: Moscone Center, West Building, Level 1
Presenter: Ghulam J. Mufti, MD, Department of Haematological Medicine, King's College London, London, United Kingdom


Abstract #3259

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib After Failure of Hypomethylating Agents (HMAs) 

Date: Sunday, December 7, 2014
Time: 6:00 PM - 8:00 PM
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Location: Moscone Center, West Building, Level 1
Presenter: Lewis R. Silverman, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY


Oral Rigosertib/Azacitidine Combination Trial Presentation:

Abstract #3252

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Date: Sunday, December 7, 2014
Time: 6:00 PM - 8:00 PM
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Location: Moscone Center, West Building, Level 1
Presenter: Shyamala C. Navada, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY


Lower Risk MDS with Rigosertib Presentation:

Abstract #3243

An in Vitro Platform to Dissect Drug Responsiveness in Refractory Anemia with Ringed Sideroblasts (RARS)

Date: Sunday, December 7, 2014
Time: 6:00 PM - 8:00 PM
Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster II
Location:  Moscone Center, West Building, Level 1
Presenter:  Siddhartha Mukherjee, MD, PhD, Department of Medicine, Division of Oncology, Columbia University Medical Center, New York, NY

MDS Epidemiology and Health Economics Presentations:

Abstract #1287

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Date: Saturday, December 6, 2014
Time:  5:30 PM - 7:30 PM
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
Location:  Moscone Center, North Building, Hall E
Presenter:  Erin P. Demakos, RN, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Abstract #1928

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Date:  Saturday, December 6, 2014
Time:  5:30 PM - 7:30 PM
Session:  637. Myelodysplastic Syndromes – Clinical Studies: Poster I
Location:  Moscone Center, West Building, Level 1
Presenter:  Christopher R. Cogle, MD, University of Florida, Gainesville, FL

Abstract #2598

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies

Date:  Sunday, December 7, 2014
Time:  6:00 PM - 8:00 PM
Session:  902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Location:  Moscone Center, North Building, Hall E
Presenter:  Sudipto Mukherjee, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH


A
b s t r a c t #2627

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Date:  Sunday, December 7, 2014
Time:  6:00 PM - 8:00 PM
Session:  902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Location:  Moscone Center, North Building, Hall E
Presenter:  Christopher R. Cogle, MD, University of Florida, Gainesville, FL

Nonclinical Stage Onconova Pipeline Compound Presentation:

Abstract # 3445 

Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition

Date:  Sunday, December 7, 2014
Time:  6:00 PM - 8:00 PM
Session:  652. Myeloma: Pathophysiology and Pre-Clinical Studies, Excluding Therapy: Poster II 
Location:  Moscone Center, West Building, Level 1
Presenter:  Deepak Perumal, PhD, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY


About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.  For more information, please visit  http://www.onconova.com . 

About Rigosertib

Rigosertib is a small molecule that inhibits cellular signaling by acting as a Ras mimetic. This is believed to be mediated by direct binding of rigosertib to the Ras-binding domain (RBD) found in many Ras effector proteins, including the Raf kinases and PI3K. The initial therapeutic focus for rigosertib is myelodysplastic syndromes (MDS), a group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukemia (AML). Clinical trials with intravenous (IV) and oral formulations of rigosertib are being conducted at leading institutions in the U.S. and abroad. To date, more than 500 MDS patients have been enrolled in clinical trials with rigosertib. Rigosertib is covered under composition of matter patents issued worldwide. Orphan designation has been granted for rigosertib in MDS in the U.S., Europe and Japan.

Onconova Therapeutics Benjamin Hoffman, 267-759-3036 or Media: MacDougall Biomedical Communications Chris Erdman, 781-235-3060

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 0

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 202

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 49

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 24

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 28

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 42

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 38

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring High ROIC Tech Stocks: Key Insights and Analysis

Updated Category News Views 284

Understanding ROIC in Tech Stocks Return on Invested Capital (ROIC) is a vital indicator when evaluating a company's financial performance and investment potential. It reflects how efficiently a firm uses the capital invested by shareholders to generate profits. High ROIC values signal that a company is not only effective in utilizing its resources but may also be poised...

Continue Reading
Join AVITA Medical's Upcoming Investor Webinar Event

Updated Category News Views 141

AVITA Medical Plans Informative Investor Webinar AVITA Medical, Inc. (NASDAQ: RCEL), known for its innovative approaches to acute wound care, is gearing up to host an insightful investor webinar. The CEO, Jim Corbett, alongside CFO, David O'Toole, will lead this engaging session and discuss the latest financial results and strategic business developments. Details of the...

Continue Reading
Labour Government's Budget Aims to Restore Market Stability

Updated Category News Views 138

Introduction to the New Labour Budget The newly formed Labour government has introduced its first budget, aiming to restore confidence in the UK markets. With a focus on substantial tax increases and strategic spending control, this budget seeks to avoid the destabilizing impact seen during Liz Truss's tenure. The measures announced are designed to bolster the economy...

Continue Reading
Beacon Energy to Host Annual General Meeting This December

Updated Category News Views 166

Beacon Energy's Annual General Meeting Update Beacon Energy plc (AIM: BCE, NYSE: BCE) is an oil and gas company dedicated to developing its onshore assets in Germany. Recently, the company confirmed that it is set to hold its Annual General Meeting (AGM) on December 18, 2024. This significant event will be hosted at 55 Athol Street, Douglas, Isle of Man, providing a prime...

Continue Reading
Okeanis Eco Tankers: Key Insights Ahead of Earnings Call

Updated Category News Views 130

Anticipating Okeanis Eco Tankers' Upcoming Earnings Okeanis Eco Tankers (NYSE:ECO) is preparing to release its latest quarterly earnings report soon. Investors and analysts are keenly focused on what this announcement will bring, particularly in terms of earnings expectations and guidance for upcoming quarters. Expected Earnings Report Industry analysts anticipate that...

Continue Reading